Oncternal Accounts Payable vs Capital Surpluse Analysis

ONCT Stock

USD 9.21 0.11 1.21%

Oncternal Therapeutics financial indicator trend analysis is much more than just breaking down Oncternal Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncternal Therapeutics is a good investment. Please check the relationship between Oncternal Therapeutics Accounts Payable and its Capital Surpluse accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.

Accounts Payable vs Capital Surpluse

Accounts Payable vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncternal Therapeutics Accounts Payable account and Capital Surpluse. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Oncternal Therapeutics' Accounts Payable and Capital Surpluse is 0.11. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Oncternal Therapeutics, assuming nothing else is changed. The correlation between historical values of Oncternal Therapeutics' Accounts Payable and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Oncternal Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Accounts Payable i.e., Oncternal Therapeutics' Accounts Payable and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.11

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Oncternal Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Oncternal Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Capital Surpluse

Most indicators from Oncternal Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncternal Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 16.78 in 2024, whereas Selling General Administrative is likely to drop slightly above 9.5 M in 2024.

	2010	2023	2024 (projected)
Reconciled Depreciation	47K	41.4K	37.2K
Discontinued Operations	13.9M	12.5M	11.1M

Reconciled Depreciation Discontinued Operations

Oncternal Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Non Currrent Assets Other	Inventory	Short Long Term Debt Total	Current Deferred Revenue	Intangible Assets
Total Assets		-0.47	-0.88	0.25	0.88	-0.04	1.0	0.13	-0.32	-0.02	1.0	-0.03	-0.02	-0.12	0.24	0.33	0.18	-0.38	0.22	-0.12	0.16	0.07	-0.01	-0.36	-0.46	-0.33
Total Stockholder Equity	-0.47		0.49	-0.5	-0.49	-0.29	-0.47	-0.16	0.7	0.09	-0.47	0.12	0.08	0.35	-0.28	-0.3	-0.02	-0.04	-0.4	0.35	-0.09	-0.58	-0.03	0.28	0.16	0.15
Net Debt	-0.88	0.49		-0.29	-1.0	0.17	-0.89	0.14	0.39	0.16	-0.88	0.19	0.14	0.02	-0.17	-0.34	-0.02	0.22	-0.08	0.02	-0.14	-0.18	0.19	0.61	0.39	0.17
Retained Earnings	0.25	-0.5	-0.29		0.3	0.71	0.25	-0.28	-0.97	-0.39	0.24	-0.4	-0.4	0.29	-0.18	0.68	-0.29	0.47	-0.34	0.29	-0.38	0.86	0.46	-0.22	-0.53	0.34
Cash	0.88	-0.49	-1.0	0.3		-0.17	0.89	-0.14	-0.39	-0.16	0.88	-0.19	-0.14	-0.03	0.17	0.34	0.02	-0.22	0.08	-0.03	0.14	0.18	-0.19	-0.61	-0.39	-0.17
Other Assets	-0.04	-0.29	0.17	0.71	-0.17		-0.05	0.19	-0.64	-0.4	-0.05	-0.37	-0.42	0.23	0.11	0.38	-0.35	0.54	-0.08	0.23	-0.55	0.7	0.69	0.18	-0.43	0.36
Cash And Short Term Investments	1.0	-0.47	-0.89	0.25	0.89	-0.05		0.1	-0.33	-0.02	1.0	-0.03	-0.01	-0.11	0.23	0.33	0.18	-0.36	0.2	-0.11	0.17	0.08	-0.03	-0.38	-0.46	-0.32
Common Stock Shares Outstanding	0.13	-0.16	0.14	-0.28	-0.14	0.19	0.1		0.21	-0.02	0.13	-0.02	-0.04	-0.53	0.63	-0.44	0.03	-0.43	0.76	-0.53	-0.2	-0.32	0.04	0.59	0.11	-0.56
Other Stockholder Equity	-0.32	0.7	0.39	-0.97	-0.39	-0.64	-0.33	0.21		0.35	-0.32	0.37	0.35	-0.15	0.08	-0.65	0.24	-0.41	0.17	-0.15	0.29	-0.88	-0.38	0.28	0.47	-0.25
Total Liab	-0.02	0.09	0.16	-0.39	-0.16	-0.4	-0.02	-0.02	0.35		-0.02	0.99	1.0	-0.32	-0.39	-0.3	0.89	-0.26	0.1	-0.32	0.87	-0.44	-0.31	0.17	0.35	-0.22
Total Current Assets	1.0	-0.47	-0.88	0.24	0.88	-0.05	1.0	0.13	-0.32	-0.02		-0.03	-0.01	-0.12	0.24	0.32	0.18	-0.38	0.23	-0.12	0.16	0.07	-0.02	-0.36	-0.45	-0.33
Other Current Liab	-0.03	0.12	0.19	-0.4	-0.19	-0.37	-0.03	-0.02	0.37	0.99	-0.03		0.99	-0.28	-0.43	-0.31	0.9	-0.22	0.07	-0.28	0.87	-0.45	-0.26	0.18	0.32	-0.17
Total Current Liabilities	-0.02	0.08	0.14	-0.4	-0.14	-0.42	-0.01	-0.04	0.35	1.0	-0.01	0.99		-0.33	-0.38	-0.3	0.88	-0.26	0.11	-0.33	0.88	-0.44	-0.34	0.14	0.37	-0.21
Property Plant And Equipment Net	-0.12	0.35	0.02	0.29	-0.03	0.23	-0.11	-0.53	-0.15	-0.32	-0.12	-0.28	-0.33		-0.25	0.62	-0.23	0.61	-0.52	1.0	-0.2	0.38	0.65	-0.5	-0.55	0.83
Accounts Payable	0.24	-0.28	-0.17	-0.18	0.17	0.11	0.23	0.63	0.08	-0.39	0.24	-0.43	-0.38	-0.25		-0.04	-0.4	-0.25	0.64	-0.25	-0.34	0.02	0.01	-0.03	-0.07	-0.32
Non Current Assets Total	0.33	-0.3	-0.34	0.68	0.34	0.38	0.33	-0.44	-0.65	-0.3	0.32	-0.31	-0.3	0.62	-0.04		-0.13	0.29	-0.3	0.62	-0.12	0.73	0.63	-0.57	-0.7	0.4
Common Stock Total Equity	0.18	-0.02	-0.02	-0.29	0.02	-0.35	0.18	0.03	0.24	0.89	0.18	0.9	0.88	-0.23	-0.4	-0.13		-0.33	0.06	-0.23	0.9	-0.38	-0.14	0.11	0.09	-0.25
Non Current Liabilities Total	-0.38	-0.04	0.22	0.47	-0.22	0.54	-0.36	-0.43	-0.41	-0.26	-0.38	-0.22	-0.26	0.61	-0.25	0.29	-0.33		-0.43	0.61	-0.26	0.65	0.45	-0.34	-0.27	0.93
Other Current Assets	0.22	-0.4	-0.08	-0.34	0.08	-0.08	0.2	0.76	0.17	0.1	0.23	0.07	0.11	-0.52	0.64	-0.3	0.06	-0.43		-0.52	0.09	-0.23	-0.09	0.15	0.25	-0.5
Property Plant And Equipment Gross	-0.12	0.35	0.02	0.29	-0.03	0.23	-0.11	-0.53	-0.15	-0.32	-0.12	-0.28	-0.33	1.0	-0.25	0.62	-0.23	0.61	-0.52		-0.2	0.38	0.65	-0.5	-0.55	0.83
Common Stock	0.16	-0.09	-0.14	-0.38	0.14	-0.55	0.17	-0.2	0.29	0.87	0.16	0.87	0.88	-0.2	-0.34	-0.12	0.9	-0.26	0.09	-0.2		-0.33	-0.33	-0.2	0.22	-0.15
Non Currrent Assets Other	0.07	-0.58	-0.18	0.86	0.18	0.7	0.08	-0.32	-0.88	-0.44	0.07	-0.45	-0.44	0.38	0.02	0.73	-0.38	0.65	-0.23	0.38	-0.33		0.52	-0.43	-0.53	0.52
Inventory	-0.01	-0.03	0.19	0.46	-0.19	0.69	-0.03	0.04	-0.38	-0.31	-0.02	-0.26	-0.34	0.65	0.01	0.63	-0.14	0.45	-0.09	0.65	-0.33	0.52		-0.03	-0.55	0.53
Short Long Term Debt Total	-0.36	0.28	0.61	-0.22	-0.61	0.18	-0.38	0.59	0.28	0.17	-0.36	0.18	0.14	-0.5	-0.03	-0.57	0.11	-0.34	0.15	-0.5	-0.2	-0.43	-0.03		0.45	-0.47
Current Deferred Revenue	-0.46	0.16	0.39	-0.53	-0.39	-0.43	-0.46	0.11	0.47	0.35	-0.45	0.32	0.37	-0.55	-0.07	-0.7	0.09	-0.27	0.25	-0.55	0.22	-0.53	-0.55	0.45		-0.31
Intangible Assets	-0.33	0.15	0.17	0.34	-0.17	0.36	-0.32	-0.56	-0.25	-0.22	-0.33	-0.17	-0.21	0.83	-0.32	0.4	-0.25	0.93	-0.5	0.83	-0.15	0.52	0.53	-0.47	-0.31

Click cells to compare fundamentals

Oncternal Therapeutics Account Relationship Matchups

Oncternal Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	21.7M	118.8M	93.6M	68.7M	36.7M	61.3M
Total Stockholder Equity	14.3M	(82.8M)	(114.1M)	(158.3M)	30.1M	31.6M
Net Debt	(19.9M)	(116.7M)	(90.7M)	(37.1M)	(6.4M)	(6.7M)
Retained Earnings	(65.6M)	(82.8M)	(114.1M)	(158.3M)	(197.8M)	(207.7M)
Cash	20.1M	116.7M	90.8M	37.1M	6.7M	6.4M
Other Assets	767K	806K	657K	1.3M	1.1M	1.7M
Cash And Short Term Investments	20.1M	116.7M	90.8M	63.7M	34.3M	55.2M
Common Stock Shares Outstanding	516.4K	1.0M	2.5M	2.6M	2.9M	3.1M
Liabilities And Stockholders Equity	21.7M	(76.9M)	(108.7M)	68.7M	36.7M	31.8M
Other Stockholder Equity	628.8M	79.9M	(49K)	(66K)	227.8M	294.2M
Total Liab	7.4M	5.9M	5.5M	7.7M	6.7M	6.3M
Total Current Assets	20.8M	118.0M	92.9M	67.3M	36.1M	58.6M
Other Current Liab	2.7M	3.0M	3.4M	4.7M	3.9M	7.3M
Total Current Liabilities	7.3M	5.9M	5.5M	7.7M	5.2M	4.9M
Property Plant And Equipment Net	190K	40K	75K	87K	258K	245.1K
Accounts Payable	871K	1.1M	2.0M	2.9M	1.1M	1.6M
Non Current Assets Total	957K	806K	732K	1.4M	670K	636.5K
Common Stock Total Equity	24K	15K	49K	57K	65.6K	50.6K
Non Current Liabilities Total	91K	2.8M	2.0M	3.0M	1.5M	1.4M
Property Plant And Equipment Gross	190K	40K	75K	87K	258K	245.1K
Common Stock	24K	15K	49K	57K	3K	2.9K
Non Currrent Assets Other	767K	766K	657K	1.3M	412K	428.8K
Accumulated Other Comprehensive Income	(2.7M)	(2.6M)	0.0	9K	3K	3.2K
Net Tangible Assets	14.4M	113.0M	88.1M	61.0M	70.1M	35.9M
Retained Earnings Total Equity	(600.1M)	(65.6M)	(82.8M)	(158.3M)	(182.0M)	(191.1M)
Capital Surpluse	626.1M	79.9M	195.7M	219.2M	197.3M	340.7M
Property Plant Equipment	190K	40K	75K	87K	78.3K	152.8K
Net Invested Capital	14.3M	113.0M	88.1M	61.0M	30.1M	58.3M
Net Working Capital	13.4M	112.1M	87.4M	59.6M	30.9M	57.8M

When determining whether Oncternal Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oncternal Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oncternal Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Oncternal Therapeutics Stock:

How To Invest In Oncternal

Details

Is Oncternal Stock a good investment?

Details

What is Oncternal Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.

Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Oncternal Stock analysis

When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	CEOs Directory Screen CEOs from public companies around the world
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(12.33)

Revenue Per Share

0.39

Quarterly Revenue Growth

1.803

Return On Assets

(0.49)

Return On Equity

(0.87)

The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncternal Accounts Payable vs Capital Surpluse Analysis

Accounts Payable vs Capital Surpluse

Accounts Payable vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Accounts Payable

Capital Surpluse

Oncternal Therapeutics fundamental ratios Correlations

Oncternal Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncternal Therapeutics fundamental ratios Accounts

Complementary Tools for Oncternal Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Liabilities	+ 1.0	Total Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Other Current Liab	+ 0.99	Total Liab

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.89	Net Debt
Non Currrent Assets Other	- 0.88	Other Stockholder Equity
Total Current Assets	- 0.88	Net Debt
Net Debt	- 0.88	Total Assets